Personalized medicine is a medical model that uses medical decisions, practices, interventions and/or products that are tailored to the individual patient based on their predicted response or risk of disease.

RSK Medical Inc. brings a wealth of experience, knowledge, progressive learning and keen responsiveness as a medical device supplier and is dedicated to providing innovative and disruptive medical device technologies to the Canadian clinical community. These provide clinicians and hospitals with improved outcomes, preventative and therapeutic long-term care for their patients.

Based on strong clinical data and engineering, our products create and deliver substantial economic value to the health care system.

Latest News

electroCore, Inc. Announces Regulatory Approval in Canada

April 5, 2021

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with Health Canada.

gammaCore Sapphire will be distributed in Canada by RSK Medical Inc., pursuant to an exclusive distribution agreement announced on January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in Canada have been waiting years for this novel migraine and cluster headache therapy. RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said Scott Kadwell, President of RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr. Elizabeth Leroux, president of the Canadian Headache Society and the founder and chair of Migraine Canada.

New Distribution Agreement with Angiodroid, manufacturer of the CO2 Injector

March 24, 2021

RSK Medical Inc. has signed a long term agreement (Canada-wide) to represent Angiodroid Srl from Bologna, Italy.

Angiodroid manufacturers The CO2 Injector, the first system for Automated Carbon Dioxide Angiography (ACDA) dedicated to diagnostic and interventional procedures in peripheral and venous systems.

The Safety and Efficacy of Angiodroid’s CO2 injector has been validated in over 20 international clinical studies to date. This technology makes it possible to use CO2, a 100% biocompatible gas to obtain high quality radiological angiographic images while preserving the renal function of the patients. The ACDA system system avoids all contrast induced nephropathy risks and potential for allergic reactions.

Angiodroid has begun preparation for submitting for Health Canada regulatory approval. Find more on www.angiodroid.com.

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

January 26, 2021

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada, supplying therapy to patients suffering with primary headache disorders.
Read more news from RSK Medical

Our People

Scott Kadwell

Scott Kadwell is the President of RSK Medical Inc. Over 40 plus years in the cardiovascular medical device business in Canada, he has held senior national business and marketing management positions with many of the largest global medical device companies such as SulzerMedica, Guidant, BSC, Medtronic and Sorin Group while residing in Calgary, Vancouver and Toronto.

The cardiovascular specialities related to his experience have been in the fields of interventional cardiology and radiology, electrophysiology, cardiac surgery and vascular/ endovascular therapies.

Scott was formerly an active member at MEDEC Association participating in a number of committees to develop policies, therapy awareness and financial reimbursement for new device technologies.

Dr. Frederick Kozak

Dr. Frederick Kozak is a Pediatric Otolaryngologist at BC Children’s Hospital and Clinical Professor in the Department of Surgery at the University of British Columbia. In his career of over twenty years, Dr. Kozak has been extensively involved as a clinician, researcher, medical educator and administrator.

His main clinical area of interest is hearing loss in the pediatric population and he is the Surgical/Medical Director of the Pediatric Cochlear Implant Program in B.C. He has published over 40 peer reviewed publications and he has presented his research and educational expertise locally, nationally and internationally. His extensive involvement in administrative committees includes being Vice-Chair and Chair of the Medical Advisory Committee for Children’s and Women’s Hospital of BC from 2002-2007.

Dr. Kozak has provided consultation to several pharmaceutical and device manufacturers over the past 20 years.

Gordon Collins

Gordon Collins is a Business Advisor, Executive Coach and Facilitator. Gordon is the president and founder of The Coaching Network based in Oakville, Ontario. He is also an associate with SGA – a consulting firm specializing in developing ‘C-Suite’ influencing capabilities globally and an adjunct faculty member of the Telfer Centre for Executive Leadership – University of Ottawa.

Gordon specializes in developing Business Effectiveness – through building leadership capability, creating team alignment and designing innovative approaches to creating competitive advantage. He has in-depth experience in the Private, Public and Non Profit sectors as well as a global practice across North and South America, Europe, Middle East, Asia Pacific and Africa.

Gordon has provided consultation to a large number of medical device, biotech and pharmaceutical companies across North America and Europe over the past 20 years.

PO Box 30040 RPO Boxgrove
90 Copper Creek Dr.
Markham, Ontario
L6B 0R5 Canada